KR880008800A - 난용성 활성성분을 위한 치료계 - Google Patents

난용성 활성성분을 위한 치료계 Download PDF

Info

Publication number
KR880008800A
KR880008800A KR1019880000168A KR880000168A KR880008800A KR 880008800 A KR880008800 A KR 880008800A KR 1019880000168 A KR1019880000168 A KR 1019880000168A KR 880000168 A KR880000168 A KR 880000168A KR 880008800 A KR880008800 A KR 880008800A
Authority
KR
South Korea
Prior art keywords
nucleus
casing
water
mixture
active ingredient
Prior art date
Application number
KR1019880000168A
Other languages
English (en)
Other versions
KR960005139B1 (ko
Inventor
칸드라 크하나 사티쉬
Original Assignee
아놀드 자일러, 에른스트 알테르
시바-가이기 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아놀드 자일러, 에른스트 알테르, 시바-가이기 에이지 filed Critical 아놀드 자일러, 에른스트 알테르
Publication of KR880008800A publication Critical patent/KR880008800A/ko
Application granted granted Critical
Publication of KR960005139B1 publication Critical patent/KR960005139B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음.

Description

난용성 활성성분을 위한 치료계
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. (a) 물에 침투성이며 활성성분을 함유하는 핵(core)의 성분에 불침투성인 물질로 만들어진 케이싱(casing). (b) 물에 난용성인 활성성분 또는 이러한 활성성분들의 혼합물, 비닐-피롤리돈/비닐 아세테이트 공중합체와 에틸렌 옥사이드 단독중합체와의 혼합물로 구성된 친수성 중합체 팽윤제, 삼투를 유발시키기 위힌 임의성분인 수용성 물질 및 임의성분인 추가의 약제학적으로 허용되는 보조제를 함유하는 핵 및 (c) 핵내에 함유된 성분을 주변 수성 체액으로 전달하기 위한 케이싱(a)을 통한 통로로 구성된, 물에 난용성인 활성성분의 투여를 위한 경구 치료제.
  2. 제1항에 있어서, (a) 물에 침투성이며 활성성분을 함유하는 핵의 성분 및 체액(예 : 위액 또는 장액) 내에 함유된 이온에 불침투성인 아실화 셀룰로스(예 : 설룰로스 아세테이트)로 만들어진 케이싱. (b) 물에 난용성이 활성성분 또는 이러한 활성성분들의 혼합물, 비닐-피롤리돈/비닐 아세테이트 공중합체와 에틸렌옥사이드 단독중합체와의 1 : 1 혼합물 (중량비), 삼투를 유발시키기 위한 염화나트륨 또는 염화칼륨 및 임의 성분인 추가의 약제학적으로 허용되는 보조제를 함유하는 핵 및 (c) 핵내에 함유된 성분을 주변 수성 체액으로 전달하기 위한 케이싱(a)을 통한 통로로 구성된 경구 치료계.
  3. 제1항에 있어서, (a) 물에 침투성이며 활성성분을 함유하는 핵의 성분 및 체액(예 : 위액 또는 장액) 내에 함유된 이온에 불침투성인 아실화 셀룰로스 (예 : 셀룰로스 아세테이트)로 만들어진 케이싱. (b) 물에 난용성인 활성성분 또는 이러한 활성성분들의 혼합물 및 60,000±15,000의 분자량 및 대략 60 : 40(중량％)의 단량체 비를 갖는 비닐-피롤리돈/비닐 아세테이트 공중합체와 2,000 내지 100,000의 중합도를 갖는 에틸렌 옥사이드 단독중합체와의 1 : 1 혼합물(중량비)을 함유하는 핵 및 (c) 핵내에 함유된 성분을 주변 수성 체액으로 전달하기 위한 케이싱(a)을 통한 통로로 구성된 경구 치료계.
  4. 제3항에 있어서, 핵(b)내에 콜리돈(kollidon)VA64과 폴리옥스(polyox)과의 1 : 1 혼합물을 함유하는 경구 치료계.
  5. 제1항 내지 4항중 어느 한 항에 있어서 정제형태인 경구 치료제.
  6. 핵의 성분을 서로 혼합하고, 핵을 케이싱으로 씌운 다음, 개방부를 케이싱내에 형성시킴을 특징으로 하여 제1항에 따르는 치료계를 제조하는 방법.
  7. 사람 또는 동물을 치료하는데 사용하기 위한 제1항에 따르는 치료계.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880000168A 1987-01-14 1988-01-13 난용성 활성 성분을 위한 치료 시스템 KR960005139B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH116/87-7 1987-01-14
CH11687 1987-01-14

Publications (2)

Publication Number Publication Date
KR880008800A true KR880008800A (ko) 1988-09-13
KR960005139B1 KR960005139B1 (ko) 1996-04-22

Family

ID=4179612

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880000168A KR960005139B1 (ko) 1987-01-14 1988-01-13 난용성 활성 성분을 위한 치료 시스템

Country Status (21)

Country Link
US (1) US4992278A (ko)
EP (1) EP0277092B1 (ko)
JP (1) JP2656933B2 (ko)
KR (1) KR960005139B1 (ko)
AT (1) ATE72111T1 (ko)
AU (1) AU604825B2 (ko)
CA (1) CA1328403C (ko)
DE (1) DE3868077D1 (ko)
DK (1) DK13688A (ko)
ES (1) ES2039287T3 (ko)
FI (1) FI92648C (ko)
GR (1) GR3003734T3 (ko)
IE (1) IE61821B1 (ko)
IL (1) IL85060A (ko)
MX (1) MX10086A (ko)
MY (1) MY102660A (ko)
NO (1) NO175564C (ko)
NZ (1) NZ223164A (ko)
PH (1) PH25901A (ko)
PT (1) PT86536B (ko)
ZA (1) ZA88211B (ko)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331563C (en) * 1987-08-03 1994-08-23 Gaylen M. Zentner Device for the controlled release of drugs with donnan-like modulation by charged insoluble resins
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5108756A (en) * 1989-01-12 1992-04-28 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
DE3932987A1 (de) * 1989-10-03 1991-04-11 Int Pharma Agentur System fuer die kontrollierte freisetzung von wirkstoffen und verfahren zu seiner herstellung
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
EP0408496A3 (en) * 1989-07-12 1992-07-01 Ciba-Geigy Ag Solid dosage form for pharmaceutical substances
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5327977A (en) * 1992-12-14 1994-07-12 Anthony Lukashuk Weeder with hollow tines
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
DE19531684A1 (de) * 1995-08-29 1997-03-06 Bayer Ag Verfahren zur Herstellung von Arzneimittelzubereitungen mit kontrollierter Freisetzung
US6361796B1 (en) * 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
EP0954291B1 (en) * 1996-10-25 2005-12-28 Shire Laboratories Inc. Soluble form osmotic dose delivery system
CN1623533A (zh) 1997-09-25 2005-06-08 拜尔公司 控释活性化合物的药物制剂
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
HUP9902351A3 (en) * 1998-07-22 2001-01-29 Pharma Pass L L C Irvine Solid compositions containing metoprolol and process for producing the same
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
KR100647901B1 (ko) * 1999-07-09 2006-11-17 보령제약 주식회사 세파클러-함유 서방성 약제조성물 및 그의 제조방법
US20020015731A1 (en) * 1999-12-23 2002-02-07 Appel Leah E. Hydrogel-Driven Drug Dosage Form
EP1239839A2 (en) 1999-12-23 2002-09-18 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
AU5459201A (en) * 2000-05-30 2001-12-11 Add Advanced Drug Delivery Technologies Ag Peroral therapeutic system comprising glipizide
IN190699B (ko) * 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
WO2003092660A1 (en) * 2002-05-06 2003-11-13 Ranbaxy Laboratories Limited Monocompartment osmotic controlled drug delivery system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20060286169A1 (en) * 2003-02-13 2006-12-21 Phares Pharmaceutical Research N.V. Lipophilic compositions
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
PT1842533E (pt) * 2003-08-06 2013-05-17 Gruenenthal Gmbh Forma de dosagem protegida contra abuso
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) * 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032051A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1690540A1 (en) * 2005-02-15 2006-08-16 Neuro3D Composition comprising ocaperidone
US8858993B2 (en) 2005-07-25 2014-10-14 Metrics, Inc. Coated tablet with zero-order or near zero-order release kinetics
US8778395B2 (en) 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
US20070128283A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
US20070128280A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
US20070128281A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
US7714201B2 (en) * 2006-12-22 2010-05-11 Monsanto Technology Llc Cotton variety 781000G
US7419684B2 (en) * 2006-12-22 2008-09-02 Reliant Pharmaceuticals, Inc. System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
NZ586792A (en) * 2008-01-25 2012-09-28 Gruenenthal Chemie Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
RU2508092C2 (ru) * 2008-05-09 2014-02-27 Грюненталь Гмбх Способ получения твердой лекарственной формы, в частности таблетки для фармацевтического применения, и способ получения прекурсора твердой лекарственной формы, в частности таблетки
CN102573805A (zh) * 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
WO2011095314A2 (en) * 2010-02-03 2011-08-11 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
RU2607499C2 (ru) 2010-09-02 2017-01-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, которая содержит анионный полимер
PL2611426T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
PT2736497T (pt) 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente a adulteração proporcionando libertação imediata de fármaco
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
MX362357B (es) 2012-04-18 2019-01-14 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
EP3003283A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
EP3878445A3 (en) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2015004245A1 (en) 2013-07-12 2015-01-15 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
EP3258916A1 (en) 2015-02-20 2017-12-27 Osmotica Kereskedelmi ES Szolgaltato KFT Controlled release oral dosage form of gaba receptor agonist with enhanced pharmacokinetics
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
MX2021000904A (es) 2018-07-24 2021-03-31 Bayer Ag Forma de dosificacion farmaceutica administrable por via oral con liberacion modificada.
EP3826619A1 (de) 2018-07-24 2021-06-02 Bayer Aktiengesellschaft Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
WO2023145120A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 薬物放出制御製剤用組成物及び薬物放出制御製剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
DE2546577B2 (de) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
GB2150830B (en) * 1983-12-05 1987-08-19 Alza Corp Drug dispenser
US4692336A (en) * 1984-03-19 1987-09-08 Alza Corporation Self controlled release device for administering beneficial agent to recipient
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.

Also Published As

Publication number Publication date
ZA88211B (en) 1989-10-25
AU604825B2 (en) 1991-01-03
NZ223164A (en) 1990-01-29
NO880124L (no) 1988-07-15
EP0277092A1 (de) 1988-08-03
EP0277092B1 (de) 1992-01-29
JP2656933B2 (ja) 1997-09-24
FI92648B (fi) 1994-09-15
CA1328403C (en) 1994-04-12
IE61821B1 (en) 1994-11-30
JPS63174922A (ja) 1988-07-19
FI92648C (fi) 1994-12-27
MX10086A (es) 1993-12-01
NO175564C (no) 1994-11-02
GR3003734T3 (ko) 1993-03-16
NO175564B (no) 1994-07-25
AU1023788A (en) 1988-07-21
IL85060A (en) 1992-01-15
FI880100A0 (fi) 1988-01-11
DK13688A (da) 1988-07-15
ATE72111T1 (de) 1992-02-15
KR960005139B1 (ko) 1996-04-22
PT86536B (pt) 1994-02-28
DE3868077D1 (de) 1992-03-12
DK13688D0 (da) 1988-01-13
ES2039287T3 (es) 1993-09-16
NO880124D0 (no) 1988-01-13
FI880100A (fi) 1988-07-15
IL85060A0 (en) 1988-06-30
MY102660A (en) 1992-08-17
US4992278A (en) 1991-02-12
PT86536A (pt) 1989-01-30
PH25901A (en) 1991-12-19
IE880085L (en) 1988-07-14

Similar Documents

Publication Publication Date Title
KR880008800A (ko) 난용성 활성성분을 위한 치료계
KR880002511A (ko) 전신작용을 나타내는 경구적 치료 시스템
US5147654A (en) Oral osmotic device for delivering nicotine
FI107699B (fi) Annostusmuoto lääkkeen annostelun ajan suhteen vaihtelevien mallien aikaansaamiseksi
US5110605A (en) Calcium polycarbophil-alginate controlled release composition and method
AU633340B2 (en) Oral osmotic device with hydrogel driving member
JP2927956B2 (ja) 液状薬品の放出のための浸透性の投与系
ES2403069T3 (es) Composición oral de liberación controlada que contiene levetiracetam
NZ501950A (en) Medicinal compositions for application to mucosa
PT88404B (pt) Forma de dosagem que compreende a libertacao de agente rapido seguida pela libertacao de agente lento
EA004443B1 (ru) Лекарственная форма для контролируемого высвобождения ципрофлоксацина для приема один раз в день
JP2002532406A (ja) 複合コーティングによる液体充填ゼラチンカプセルの放出制御システムへの変換
PT1251832E (pt) Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
JPS62267221A (ja) 新規薬物製剤
EP0540623B1 (en) Oral osmotic device for delivering nicotine
JP2008540437A (ja) キニーネを含有する制御放出調合剤
KR940011442B1 (ko) 개선된 약제 투약시스템
JP2840446B2 (ja) 可溶性又は不溶性薬剤の送出用投薬剤形
KR880007073A (ko) 의 약 품
EP1326592B1 (en) Use of polyethylene glycol ( peg ) for the manufacture of a medicament for the treatment of constipation
JP2003055193A (ja) 清涼化剤含有ゲル状外用剤
Çiftçi et al. Formulation and in vitro-in vivo evaluation of sustained-release lithium carbonate tablets
JP2764581B2 (ja) 腸内拡散の速い新規ピコスルファートナトリウム製剤
Ten Tije et al. Intraperitoneal cisplatin in the treatment of refractory or recurrent advanced ovarian carcinoma
EP0137364A2 (en) Suppository form of an osmotic therapeutic system

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee